Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Life Sciences Limited

http://www.glenmarklifesciences.com

Latest From Glenmark Life Sciences Limited

Glenmark Reaps Favipiravir Gains, Progresses COVID-19 Nasal Spray

Strong run on Indian market for Glenmark in fiscal Q1, with the company optimistic of prospects for new introductions including generic Brovana in the US, where it expects close to double-digit growth in Q2. All eyes are also on the launch timelines of a partnered nitric oxide nasal spray for COVID-19.

Commercial Coronavirus COVID-19

Glenmark Reaps Favipiravir Gains, Progresses COVID-19 Nasal Spray

Strong run on Indian market for Glenmark in fiscal Q1, with the company optimistic of prospects for new introductions including generic Brovana in the US, where it expects close to double-digit growth in Q2. All eyes are also on the launch timelines of a partnered nitric oxide nasal spray for COVID-19.

Commercial Coronavirus COVID-19

Crunch Time For Glenmark’s US Innovation Arm, Founding CEO To Exit

Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.

Commercial Deals
See All

Company Information

UsernamePublicRestriction

Register